Reata Pharmaceuticals Overview
- Founded
- 2002

- Status
- Public
- Employees
- 349

- Stock Symbol
- RETA

- Share Price
- $27.80
- (As of Thursday Closing)
Reata Pharmaceuticals General Information
Description
Reata Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing therapeutics to address serious and life-threatening diseases by targeting molecular pathways. The company's product in the pipeline include bardoxolone methyl; Omaveloxolone and others.
Contact Information
- 5320 Legacy Drive
- Plano, TX 75024
- United States
Reata Pharmaceuticals Stock Performance
(As of Thursday Closing)
Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
---|---|---|---|---|---|---|
$27.80 | $26.88 | $20.23 - $153.41 | $1.01B | 36.5M | 671K | -$8.35 |
Reata Pharmaceuticals Financials Summary
In Thousands, USD |
TTM 31-Mar-2022 | FY 2021 31-Dec-2021 | FY 2020 31-Dec-2020 | FY 2019 31-Dec-2019 |
---|---|---|---|---|
EV | 738,367 | 246,440 | 3,886,366 | 6,592,799 |
Revenue | 11,459 | 11,490 | 9,019 | 26,517 |
EBITDA | (252,633) | (243,559) | (235,093) | (284,281) |
Net Income | (303,773) | (297,386) | (247,752) | (290,170) |
Total Assets | 679,868 | 735,016 | 857,598 | 682,420 |
Total Debt | 141,587 | 136,033 | 5,323 | 155,017 |
Reata Pharmaceuticals Valuation & Funding
Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
---|
This information is available in the PitchBook Platform. To explore Reata Pharmaceuticals‘s full profile, request access.
Request a free trialReata Pharmaceuticals Cap Table
Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
---|
This information is available in the PitchBook Platform. To explore Reata Pharmaceuticals‘s full profile, request access.
Request a free trialReata Pharmaceuticals Comparisons
Industry
00000000
00000000
PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.
Request a free trialReata Pharmaceuticals Competitors (89)
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
Catalyst Biosciences | Formerly VC-backed | South San Francisco, CA | 00 | 00000 | 000000000 | 00000 |
0000000000000 | Corporation | Shelton, CT | 00 | 000.00 | 000000000 | 000.00 |
0000000 | Venture Capital-Backed | Hannover, Germany | 00 | 00000 | 00000000000 | 00000 |
00000000 | Venture Capital-Backed | New Haven, CT | 00 | 00000 | 00000000 | 00000 |
000000000 00000000 | Formerly VC-backed | San Diego, CA | 000 | 00000 | 000000000 | 00000 |
Reata Pharmaceuticals Patents
Reata Pharmaceuticals Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
US-20210040142-A1 | C17 polar-substituted heteroaromatic synthetic triterpenoids and methods of use thereof | Pending | 19-Jul-2019 | 0000000000 | |
US-20210147380-A1 | Cysteine-dependent inverse agonists of nuclear receptors ror-gamma/ror-gamma-t and methods of treating diseases or disorders therewith | Pending | 20-Jun-2018 | 0000000000 | |
EP-3810141-A1 | Cysteine-dependent inverse agonists of nuclear receptors ror-gamma/ror-gamma-t and methods of treating diseases or disorders therewith | Pending | 20-Jun-2018 | 0000000000 | |
AU-2019286531-A1 | Pyrazole and imidazole compounds for inhibition of il-17 and rorgamma | Pending | 15-Jun-2018 | 0000000000 | |
CA-3103726-A1 | Pyrazole and imidazole compounds for inhibition of il-17 and rorgamma | Pending | 15-Jun-2018 | C07D231/54 |
Reata Pharmaceuticals Executive Team (19)
Reata Pharmaceuticals Board Members (12)
Name | Representing | Role | Since |
---|---|---|---|
Jack Nielsen | Self | Board Member | 000 0000 |
Martin Edwards MD | Self | Board Member | 000 0000 |
R. Kent McGaughy Jr. | Self | Board Member | 000 0000 |
Shamim Ruff | Reata Pharmaceuticals | Board Member | 000 0000 |
William McClellan Jr. | Self | Board Member | 000 0000 |
Reata Pharmaceuticals Signals
Growth Rate

Growth

Size Multiple


Key Data Points
Twitter Followers
5.5k

Similarweb Unique Visitors
15.0K

Majestic Referring Domains
314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.
Request a free trialReata Pharmaceuticals Investors
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|
This information is available in the PitchBook Platform. To explore Reata Pharmaceuticals‘s full profile, request access.
Request a free trial